The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., Jul. 26, 12:04 PM

Slide #8. Heat Biologics, Inc. Secondary Offering

Company: Heat Biologics, Inc. (NASDAQ:HTBX)
Date announced: 7/21/2016
Secondary Offering Details: Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced today that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by Heat. Heat intends to grant the underwriters a 45-day option to purchase up to an additional 15 percent of the securities to be sold. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Heat Biologics is a biopharmaceutical company engaged in developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. Co.'s proprietary ImPACT™ Immune Pan Antigen Cytotoxic Therapy is designed to deliver live, genetically-modified, irradiated human cells which secrete a spectrum of disease-associated antigens together with a potent immune response stimulator called gp96. The secreted antigen-gp96 educates and activates a patient's immune system to recognize and kill diseased cells. Co. has two product candidates: HS-110, which is for non-small cell lung cancer; and HS-410, which is for bladder cancer.
Open the HTBX Page at The Online Investor »

Company Name:  Heat Biologics Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding HTBX:  1
Total Market Value Held by ETFs:  $1213
Total Market Capitalization:  $13.00M
% of Market Cap. Held by ETFs:  0.01%

Open the HTBX Page at The Online Investor (in a new window) »

July 26, 2016    12:04 PM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
89th percentile
(ranked higher than approx. 89% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.